BiotechTube

Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate Chronic Plaque Psoriasis

Conditions

Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis

Trial Timeline

Nov 21, 2022 → Sep 19, 2023

NCT ID
NCT05637515

About Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe

Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe is a phase 3 stage product being developed by Biocon for Moderate Chronic Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05637515. Target conditions include Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05637515Phase 3Completed

Competing Products

20 competing products in Moderate Chronic Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
PexidartinibDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
Ranirestat + PlaceboEisaiPhase 2/3
65
E6007 + PlaceboEisaiPhase 2
52
KHK4827 + PlaceboKyowa KirinPhase 3
77
KHK4827 + PlaceboKyowa KirinPhase 3
77
KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
85
KHK4827 + PlaceboKyowa KirinPhase 2
52
Stelara + Bmab1200BioconPhase 3
77

Other Products from Biocon

Stelara + Bmab1200Phase 3
77
EQ001 + EQ001 PlaceboPhase 3
77
Itolizumab + EQ001 PlaceboPhase 3
77
Bmab 1000 + Prolia®Phase 3
77
PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelPhase 3
77